isoxazoles has been researched along with Diabetes Mellitus in 12 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (8.33) | 18.7374 |
| 1990's | 2 (16.67) | 18.2507 |
| 2000's | 5 (41.67) | 29.6817 |
| 2010's | 3 (25.00) | 24.3611 |
| 2020's | 1 (8.33) | 2.80 |
| Authors | Studies |
|---|---|
| Abdelhamid, HN; Abdulkhair, BY; Algethami, FK; Ben Jannet, H; Chrouda, A; Elamin, MR; Saidi, I | 1 |
| Fujioka, K | 1 |
| Choi, JW; Jun, HS; Jung, JY; Li, HY; Oh, YS | 1 |
| Arita, E; Auwerx, J; Horai, Y; Houten, SM; Itoh, H; Mataki, C; Morimoto, K; Sato, H; Schoonjans, K; Sugizaki, T; Tanigawara, Y; Watanabe, M | 1 |
| Bymaster, FP; Cowley, MA; Gadde, KM; Krishnan, RK; Landbloom, RP; McKinney, AA; Sinnayah, P; Tollefson, GD; Wallingford, NM | 1 |
| Chong, AS; Foster, P; Guo, Z; Jensik, SC; McChesney, L; Mital, D; Sankary, H; Shen, J; Tian, Y; Williams, JW | 1 |
| Kadowaki, T | 1 |
| Kakimoto, K; Shibata, T; Takeuchi, S; Wakitani, K; Yokota, S; Yonemori, F | 1 |
| Hasegawa, M; Makino, H; Nishimiya, T; Ochi, M; Onuma, H; Osawa, H; Tang, Y | 1 |
| Fehr, T; Ochsenbein, AF; Pinschewer, DD; Zinkernagel, RM | 1 |
| Shinkai, H | 1 |
| Bonetti, A; D'Antuono, A; Magnati, G; Pugnoli, C; Strata, A; Tirelli, F; Zuliani, U | 1 |
3 review(s) available for isoxazoles and Diabetes Mellitus
| Article | Year |
|---|---|
Current and emerging medications for overweight or obesity in people with comorbidities.
Topics: Anti-Obesity Agents; Bupropion; Cinnamates; Comorbidity; Cyclohexanes; Diabetes Mellitus; Dyslipidemias; Epoxy Compounds; Humans; Hypertension; Isoxazoles; Obesity; Overweight; Prediabetic State; Sesquiterpenes; Weight Loss; Zonisamide | 2015 |
[Insulin-sensitizing agents].
Topics: Animals; Diabetes Mellitus; Diabetes Mellitus, Experimental; Humans; Hypoglycemic Agents; Isoxazoles; Pioglitazone; Rosiglitazone; Thiazoles; Thiazolidinediones | 1999 |
[The chemical structure and pharmacological properties of a novel isoxazolidinedione insulin sensitizer, JTT-501].
Topics: Animals; Diabetes Mellitus; Diabetic Angiopathies; Diabetic Neuropathies; Glucose Transporter Type 4; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Isoxazoles; Monosaccharide Transport Proteins; Muscle Proteins; Rats; Receptors, Cytoplasmic and Nuclear; Signal Transduction; Transcription Factors | 2001 |
1 trial(s) available for isoxazoles and Diabetes Mellitus
| Article | Year |
|---|---|
[Clinico-pharmacological study of a new oral hypoglycemic agent].
Topics: Adult; Aged; Clinical Trials as Topic; Diabetes Mellitus; Drug Evaluation; Female; Glyburide; Humans; Isoxazoles; Male; Middle Aged; Placebos | 1978 |
8 other study(ies) available for isoxazoles and Diabetes Mellitus
| Article | Year |
|---|---|
Trifluoromethylated Flavonoid-Based Isoxazoles as Antidiabetic and Anti-Obesity Agents: Synthesis, In Vitro
Topics: alpha-Amylases; alpha-Glucosidases; Anti-Obesity Agents; Diabetes Mellitus; Flavonoids; Glycoside Hydrolase Inhibitors; Humans; Hypoglycemic Agents; Isoxazoles; Molecular Docking Simulation; Structure-Activity Relationship | 2021 |
Blocking lysophosphatidic acid receptor 1 signaling inhibits diabetic nephropathy in db/db mice.
Topics: Animals; Cell Line; Diabetes Mellitus; Diabetic Nephropathies; Disease Models, Animal; Disease Progression; Glycogen Synthase Kinase 3 beta; Isoxazoles; Kidney Cortex; Lysophospholipids; Male; Mice, Inbred C57BL; Phosphoric Diester Hydrolases; Phosphorylation; Propionates; Receptors, Lysophosphatidic Acid; RNA Interference; Signal Transduction; Smad2 Protein; Smad3 Protein; Sterol Regulatory Element Binding Protein 1; Time Factors; Transfection; Transforming Growth Factor beta | 2017 |
Lowering bile acid pool size with a synthetic farnesoid X receptor (FXR) agonist induces obesity and diabetes through reduced energy expenditure.
Topics: 3T3-L1 Cells; Animals; Bile Acids and Salts; Body Weight; Diabetes Mellitus; Dietary Fats; Energy Metabolism; Isoxazoles; Metabolic Syndrome; Mice; Obesity; Receptors, Cytoplasmic and Nuclear | 2011 |
Zonisamide prevents olanzapine-associated hyperphagia, weight gain, and elevated blood glucose in rats.
Topics: Animals; Anticonvulsants; Appetite Regulation; Benzodiazepines; Biomarkers; Body Weight; Diabetes Mellitus; Female; Hyperglycemia; Hyperphagia; Hypothalamic Area, Lateral; Intracellular Signaling Peptides and Proteins; Isoxazoles; Neurons; Neuropeptides; Nucleus Accumbens; Obesity; Olanzapine; Orexins; Proto-Oncogene Proteins c-fos; Rats; Rats, Sprague-Dawley; Selective Serotonin Reuptake Inhibitors; Treatment Outcome; Weight Gain; Zonisamide | 2008 |
Immunosuppression preventing concordant xenogeneic islet graft rejection is not sufficient to prevent recurrence of autoimmune diabetes in nonobese diabetic mice.
Topics: Animals; Autoimmune Diseases; Diabetes Mellitus; Diabetes Mellitus, Experimental; Female; Graft Rejection; Immunosuppression Therapy; Immunosuppressive Agents; Islets of Langerhans Transplantation; Isoxazoles; Leflunomide; Mice; Mice, Inbred NOD; Mice, Inbred Strains; Rats; Rats, Sprague-Dawley; Recurrence; Transplantation, Heterologous | 1998 |
Effects of peroxisome proliferator-activated receptor-alpha and -gamma agonist, JTT-501, on diabetic complications in Zucker diabetic fatty rats.
Topics: Absorptiometry, Photon; Animals; Body Weight; Bone Density; Bone Diseases, Metabolic; Cataract; Chromans; Diabetes Complications; Diabetes Mellitus; Diabetic Nephropathies; Diabetic Neuropathies; Eating; Hypoglycemic Agents; Isoxazoles; Male; Neural Conduction; Obesity; Pancreas; Rats; Rats, Zucker; Receptors, Cytoplasmic and Nuclear; Thiazoles; Thiazolidinediones; Time Factors; Transcription Factors; Troglitazone | 2000 |
Adipocyte-specific reduction of phosphodiesterase 3B gene expression and its restoration by JTT-501 in the obese, diabetic KKAy mouse.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Adipocytes; Adipose Tissue; Animals; Blood Glucose; Blotting, Western; Cyclic Nucleotide Phosphodiesterases, Type 3; Diabetes Mellitus; Diabetes Mellitus, Experimental; Epididymis; Fatty Acids; Female; Gene Expression Regulation, Enzymologic; Hypoglycemic Agents; Insulin; Insulin Resistance; Isoxazoles; Liver; Male; Mice; Mice, Inbred C57BL; Obesity; RNA, Messenger; Triglycerides | 2001 |
Leflunomide-mediated suppression of antiviral antibody and Tcell responses: differential restoration by uridine.
Topics: Animals; Antibodies, Viral; Antibody Formation; Autoimmune Diseases; CD8-Positive T-Lymphocytes; Diabetes Mellitus; Dose-Response Relationship, Drug; Immunosuppressive Agents; Isoxazoles; Leflunomide; Lymphocytic choriomeningitis virus; Mice; Mice, Inbred C57BL; Mice, Transgenic; T-Lymphocytes; T-Lymphocytes, Cytotoxic; Uridine; Vesicular stomatitis Indiana virus | 2001 |